Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome.

Nakagami H, Pang Z, Shimosato T, Moritani T, Kurinami H, Koriyama H, Tenma A, Shimamura M, Morishita R.

Hypertens Res. 2014 Jul;37(7):629-35. doi: 10.1038/hr.2014.53. Epub 2014 Mar 13.

PMID:
24621463
2.

A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.

Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S.

Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202. doi: 10.1016/j.ejphar.2012.09.024. Epub 2012 Sep 26.

PMID:
23022337
3.

The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.

Fukuda-Tsuru S, Kakimoto T, Utsumi H, Kiuchi S, Ishii S.

Eur J Pharmacol. 2014 Jan 15;723:207-15. doi: 10.1016/j.ejphar.2013.11.030. Epub 2013 Dec 3.

PMID:
24309217
4.

Teneligliptin : expectations for its pleiotropic action.

Morishita R, Nakagami H.

Expert Opin Pharmacother. 2015 Feb;16(3):417-26. doi: 10.1517/14656566.2015.1000301. Review.

PMID:
25597385
5.

A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats.

Kimura S, Inoguchi T, Yamasaki T, Yamato M, Ide M, Sonoda N, Yamada K, Takayanagi R.

Metabolism. 2016 Mar;65(3):138-45. doi: 10.1016/j.metabol.2015.10.030. Epub 2015 Nov 2.

PMID:
26892525
6.

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.

Ito R, Fukui T, Hayashi T, Osamura A, Ohara M, Hara N, Higuchi A, Yamamoto T, Hirano T.

Drugs R D. 2015 Sep;15(3):245-51. doi: 10.1007/s40268-015-0096-6.

7.

Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.

Jackson EK, Dubinion JH, Mi Z.

Clin Exp Pharmacol Physiol. 2008 Jan;35(1):29-34.

PMID:
18047624
8.

Long-term renal denervation normalizes disrupted blood pressure circadian rhythm and ameliorates cardiovascular injury in a rat model of metabolic syndrome.

Katayama T, Sueta D, Kataoka K, Hasegawa Y, Koibuchi N, Toyama K, Uekawa K, Mingjie M, Nakagawa T, Maeda M, Ogawa H, Kim-Mitsuyama S.

J Am Heart Assoc. 2013 Aug 23;2(4):e000197. doi: 10.1161/JAHA.113.000197.

9.

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.

Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Yoshida K, Kiuchi S, Ikenaga Y, Nakamaru Y, Hikida K, Saito A, Arakawa K, Oka K, Ueta K, Shiotani M.

J Pharmacol Sci. 2015 Apr;127(4):456-61. doi: 10.1016/j.jphs.2015.03.006. Epub 2015 Mar 28.

10.

High-phosphorus/zinc-free diet aggravates hypertension and cardiac dysfunction in a rat model of the metabolic syndrome.

Suzuki Y, Mitsushima S, Kato A, Yamaguchi T, Ichihara S.

Cardiovasc Pathol. 2014 Jan-Feb;23(1):43-9. doi: 10.1016/j.carpath.2013.06.004. Epub 2013 Aug 8.

PMID:
23932324
11.

Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.

Sueta D, Nakamura T, Dong YF, Kataoka K, Koibuchi N, Yamamoto E, Toyama K, Yasuda O, Ogawa H, Kim-Mitsuyama S.

Am J Hypertens. 2012 Jun;25(6):704-10. doi: 10.1038/ajh.2012.26. Epub 2012 Mar 15.

PMID:
22421905
12.

Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: The Contribution of Glucagon-like Peptide-1.

Moroi M, Kubota T.

J Cardiovasc Pharmacol. 2015 Aug;66(2):159-64. doi: 10.1097/FJC.0000000000000258.

PMID:
25853991
13.

A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice.

Nakamura K, Fukunishi S, Yokohama K, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K.

Int J Mol Med. 2017 Apr;39(4):969-983. doi: 10.3892/ijmm.2017.2899. Epub 2017 Feb 20.

PMID:
28260070
14.

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.

Ideta T, Shirakami Y, Miyazaki T, Kochi T, Sakai H, Moriwaki H, Shimizu M.

Int J Mol Sci. 2015 Dec 8;16(12):29207-18. doi: 10.3390/ijms161226156.

15.

[Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA(®)].

Goda M, Akahoshi F, Ishii S, Terata R, Hayashi Y.

Nihon Yakurigaku Zasshi. 2013 Sep;142(3):134-43. Review. Japanese. No abstract available.

PMID:
24025495
16.

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N, Sekiguchi S, Ishige T, Shima K, Nabeno M, Abe Y, Anabuki J, Soejima A, Yoshida K, Takashina Y, Ishii S, Kiuchi S, Fukuda S, Tsutsumiuchi R, Kosaka K, Murozono T, Nakamaru Y, Utsumi H, Masutomi N, Kishida H, Miyaguchi I, Hayashi Y.

Bioorg Med Chem. 2012 Oct 1;20(19):5705-19. doi: 10.1016/j.bmc.2012.08.012. Epub 2012 Aug 17.

PMID:
22959556
17.

Low-intensity voluntary running lowers blood pressure with simultaneous improvement in endothelium-dependent vasodilatation and insulin sensitivity in aged spontaneously hypertensive rats.

Sun MW, Qian FL, Wang J, Tao T, Guo J, Wang L, Lu AY, Chen H.

Hypertens Res. 2008 Mar;31(3):543-52. doi: 10.1291/hypres.31.543.

PMID:
18497475
18.

DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes.

Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Tsutsumi K, Miyata T.

Drug Res (Stuttg). 2015 Oct;65(10):532-4. doi: 10.1055/s-0034-1390419. Epub 2014 Nov 4.

PMID:
25368904
19.

Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp.

Hussein G, Nakagawa T, Goto H, Shimada Y, Matsumoto K, Sankawa U, Watanabe H.

Life Sci. 2007 Jan 16;80(6):522-9. Epub 2006 Oct 12.

PMID:
17074368
20.

Diet modification and its influence on metabolic and related pathological alterations in the SHR/NDmcr-cp rat, an animal model of the metabolic syndrome.

Kawai K, Sakairi T, Harada S, Shinozuka J, Ide M, Sato H, Tanaka M, Toriumi W, Kume E.

Exp Toxicol Pathol. 2012 May;64(4):333-8. doi: 10.1016/j.etp.2010.09.006. Epub 2010 Oct 20.

PMID:
20965707

Supplemental Content

Support Center